Summary The aim of this study was to determine the apoptotic cell death in 92 thyroid carcinomas of different histotypes (42 papillary, PTC; 12 poorly differentiated, PDC; 21 undifferentiated, UC; and 17 medullary, MC) by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick end labelling (TUNEL). Apoptotic index (Al, evaluated as a percentage of TUNEL-positive cells of neoplastic cells) was calculated in each tumour. The Al was very low in all subtypes of thyroid carcinoma, ranging from a median value of 0.2 in PTC to 1.4 in UC. The proliferative activity was determined by immunohistochemistry using monoclonal antibody, MIB-1. The percentage of proliferating cells was significantly different among the histotypes, increasing with tumour aggressiveness (from the mean value of 3.1 for PTC to 5.6 for PDC and 51.8 for UC). In addition, the ratio between proliferative activity and apoptosis was significantly higher in UC than in the other histotypes. The expression of bcl-2 and p53 protein (important in the modulation of cell death) was correlated (bcl-2, inverse correlation, r2 = 0.1, P= 0.04; p53, direct correlation, r2= 0.11, P= 0.02) with apoptotic index in PTC.
MATERIALS AND METHODS Patients and follow up
The study was carried out on 92 patients with primary malignant thyroid tumours. The histological diagnoses of the tumours, according to WHO (Hedinger, 1988) and subsequent updating (Sakamoto et al, 1983; Rosai et al, 1990; Johnson et al; Sobrinho-Simoes, 1995) were as follows: 42 PTC, 12 PDC, 21 UC and 17 MC. The PTCs consisted of the following variants according to WHO: 12 follicular and 30 not otherwise specified. The 12 PDC were represented by five insular carcinomas, five oxyphilic carcinomas and two trabecular carcinomas. This series of thyroid tumours is part of a larger series of thyroid cancer patients followed at the Institute of Endocrinology, which is a referral centre for thyroid carcinomas in Italy. We studied all patients who received primary surgical treatment at the University of Pisa and whose tissues were available at the Department of Pathology.
Initial treatment was total (near-total) thyroidectomy in all patients, regardless of the histotype. Lymph node dissection was performed on principle in MC, but not in PTC, in which lymph node dissection was performed only in the case of evident node involvement. Post-surgical treatment included '13I therapy for PTC and PDC [if iodine uptake of whole body scan (WBS) with 1311 was demonstrated] followed by L-thyroxine suppressive therapy. MC and PDC (with no iodine uptake) were treated with chemotherapy and/or radiotherapy in case of recurrence or distant metastases. UC were treated with total thyroidectomy whenever possible, followed by external radiotherapy and/or chemotherapy. All patients were regularly followed up by physical examination, chest radiograph and WBS with 1311 (PTC).
Analysis of programmed cell death by the terminal transferase assay
Paraffin-embedded sections of thyroid tumours were deparaffinized in xylene twice for 5 min and then rehydrated in 100%, 95%, 75% and 50% ethanol for 3 min each. After rehydration, sections were washed in phosphate-buffered saline (PBS) containing 0.5% hydrogen peroxide to inactivate endogenous peroxidase, and then incubated with 20 jg ml-' proteinase K in PBS. DNA fragments in the tissue section were determined using ApopTag Plus in situ apoptosis detection kit (Oncor, Gaithersburg, MD, USA). The labelling procedure was performed following the supplier's instructions. Briefly, the enzyme, terminal deoxynucleotidyl tranferase (TdT), which catalyses a templateindependent addition of deoxyribonucleotide to 3'-OH ends of DNA, was used to incorporate digoxigenin-conjugated dUTP to the ends of DNA fragments. The signal of TdT-mediated dUTP nick end labelling (TUNEL) was than detected by an anti-digoxigenin antibody conjugated with peroxidase, a reported enzyme that catalytically generates a brown-coloured product from the chromogenic substrate, diaminobenzidine. The labelling conditions were optimized by adjusting incubation time and concentrations of TdT. After TUNEL, counterstaining was performed by immersing the slides in 0.5% methyl green in 0.1 mol 1-1 sodium acetate solution (pH 4.0) for 5 min at room temperature. The slides were washed, dried and mounted in Permount medium. Cell counting was performed with a light microscope. For each slide, 1000 cells were counted in random fields of each section at high power. The cells with clear nuclear labelling were defined as TUNEL-positive cells. Since apoptotic cells were often identified in the compromised rim of necrotic zones, such areas were not included in assessing AI. As positive control, sections of normal colonic mucosa or lymph node were used. The apoptotic index was calculated as percentage of TUNEL-positive cells using the following formula:
Apoptotic index = 100 x (number of TUNEL-positive cells/ number of total cell nuclei).
Immunohistochemistry
Immediately after surgery, the tissues were formalin fixed, paraffin embedded and stained with haematoxylin and eosin.
bcl-2 expression Paraffin sections (3-5 jim) were dewaxed in xylene and rehydrated through graded alcohols. Sections were blocked with 10% normal rabbit serum for 30 min before adding monoclonal antibody against bcl-2 (MAb 124; DBA Italia, Milan, Italy) for 18-24 h at 1:20 dilution. The alkaline phosphatase-antialkaline phosphatase (APAAP) method (Cordell et al, 1984) was then used to amplify the primary antibody signal; the sections were incubated with rabbit anti-mouse antibody for 30 min, and then with mouse monoclonal APAAP for another 30 min. These two steps were then repeated once for 10 min each. The reaction was evidenced using alkaline phosphatase substrate containing naphthol AS-MX, fast-red and levamisol (APAAP kits, Dako SpA, Milan, Italy) yielding an insoluble red reaction product. Sections were counterstained with Gill's haematoxylin and then mounted in aqueous mounting medium. Formalin-fixed, paraffin-embedded sections from tonsillar tissue were used as positive control. As negative control, we used PBS instead of primary MAb. p53 and MIBI expression Sections (3-5 jim) were stained using the avidin-biotin-peroxidase complex (ABC) method. Briefly, dewaxed sections were treated with 0.3% hydrogen peroxidase in methanol for 30 min to block the endogenous peroxidase. In order to unmask the p53 and Ki-67 epitopes, we microwaved the sections in 10 mm citrate buffer, pH 6.0 (Cattoretti et al, 1992 
RESULTS

Apoptosis in thyroid carcinomas
Apoptotic cells contain fragments of genomic DNA in their nuclei. The TUNEL method can detect these cells in situ by labelling the end of DNA fragments. We used this method to analyse apoptosis in thyroid tissues by incorporating digoxigenin-conjugated dUTP into the DNA fragments with the enzyme TdT. As shown in Figure  1 , few cells showed positive TUNEL nuclei, which appear dark 
MIB-1 expression in thyroid carcinomas
The mean MIB-1-positive cell rate was significantly different in thyroid carcinoma subtypes. As reported in Table 1 , MIB-1-positive cell rate was very low in PTC (3.1 ± 2.9), quite high in PDC (5.6 ± 5.9) and MC (5.1 ± 5.3), and increased significantly (Fisher's exact test) in UC (51.8 ± 23) (Figure 2 ). Ratio between proliferative activity and apoptotic index
We evaluated the ratio between the percentage of MIB-1 positive cells and the apoptotic cells in 92 thyroid carcinomas. As expected, the value of this ratio was significantly higher (Fisher's exact test) in UC than in the other histotypes (Table 1) .
Correlation between bcl-2, p53 and apoptotic index 
DISCUSSION
Apoptosis plays an important role in developmental biology, autoimmune disease and tumour growth (Barr and Tomei, 1994) . It is known that, in a tumour a balance between cell proliferation and apoptotic cell death is a crucial event in its net growth rate (Williams, 1991) . In the present study, we report the percentage of apoptotic cells in different histotypes of thyroid tumours. In the same tumours, we also evaluate the proliferative activity by using the MIB-1 antibody generated against recombinant parts of the Ki-67 antigen, which is present in GI, S, G2 and M phases (Cattoretti et al, 1992) . The apoptotic fraction was 0.2 in well-differentiated papillary thyroid carcinomas as well as in poorly differentiated carcinomas, 0.6 in medullary carcinoma and 1.4 in undifferentiated tumours. These results suggest that the percentage of apoptotic cells increases in the more advanced stage of thyroid tumours. Our results are in agreement with those reported by Staunton and Gaffney (1995) and Tanimoto et al (1995) , who reported an apoptotic index ranging from 0 to 1.2 in papillary thyroid carcinoma and a value from 1.9 to 2.9 in anaplastic subtypes. Taken together, these results suggest that thyroid neoplastic progression is directly correlated to the increase of apoptotic index. In contrast to the results that we and others have obtained in thyroid cancer, Bedi et al (1995) found that the transformation of colorectal epithelium to carcinoma was associated with a progressive inhibition of apoptosis, although recently Tatebe et al (1996) have reported that apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas. In neuroblastoma, Gestblom et al (1995) reported that high density of apoptotic cells indicates favourable outcome in patients. In contrast, a high apoptotic index seems to be associated with features of poor prognosis in endometrial adenocarcinoma (Heatley, 1995) . Moreover, in oesophageal squamous cell carcinomas, it has been shown that apoptosis labelling index increases progressively from cancer localized only in the mucosa to cancer invading the muscularis propria and/or adventitia (Ohbu et al, 1995) . These authors paper suggests that single cell death becomes more frequent as tumour volume increases, a mechanism which is similar to that of the normal epidermis.
Proliferative activity is an important prognostic marker in several types of cancer (Hofstadter et al, 1995) , including thyroid tumours (Katoh et al, 1995) . Several methodologies have been used to study the growth potential of neoplastic and non-neoplastic tissues, i.e. [3H]thymidine autoradiography, measurement of DNA content, proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibody. The development of the new monoclonal antibody, MIB-1, aimed against recombinant parts of the Ki-67 antigen, able to work (in contrast to Ki-67 MAb) in paraffinembedded material, allows us to analyse retrospective cases. As already reported recently (Katoh et al, 1995) , well-differentiated carcinomas (papillary and follicular) have the lowest proliferative activity, poorly differentiated carcinomas show a medium range of proliferative cells, while undifferentiated carcinoma present a significant increase of this 'marker'. Since tumour growth is affected by both cell proliferation and cell death, we believe the ratio between these two parameters may be more significant than the analysis of the single marker. The results obtained clearly indicate that this value is more than double in UC than in PTC, and three times higher in comparison with medullary carcinomas.
Since it is known that apoptosis is regulated by bcl-2 and p53, we correlated the expression of the protein encoded by these two genes with the apoptotic index. The bcl-2 proto-oncogene is shown to confer resistance to apoptotic cell death (Craig, 1995) and is restricted to the long-lived progenitor cells requiring an extended life-span (Hockenbery et al, 1991) . We and others (Pollina et al, 1996; Pilotti et al, 1994) have reported recently that in the thyroid, both from fetal and adult tissue, as well as in differentiated carcinomas, the bcl-2 protein is highly expressed. Conversely, the expression of the same protein is significantly reduced in undifferentiated tumours. Since bcl-2 is an antidote to programmed cell death, we attempt to correlate the bcl-2 protein to the number of apoptotic cells in the different histotype of thyroid tumours. We have found that in the PTC group the bcl-2 protein expression was inversely correlated to percentage of apoptotic cells, suggesting that the low percentage of apoptotic cells is at least partly a result of the high expression of bcl-2 protein.
The p53 tumour-suppressor protein is a potent inhibitor of cell growth and transformation, and is involved in the cellular response to DNA damage (Merlo et al, 1995) . The DNA damage-induced cell cycle arrest requires wild-type p53 function (Canman et al, 1995) . A number of experiments have also indicated that wild-type p53 can mediate DNA damage-induced programmed cell death, presumably when the damage is excessive and incompatible with DNA replication. p53 protein is expressed at very low levels in differentiated thyroid carcinomas, whereas it is highly expressed in undifferentiated cancers. Like bcl-2, the expression of p53 is directly correlated to the apoptotic index only in the papillary form of thyroid cancer. These data further confirm that p53 is also an inducer of PCD in vivo, while bcl-2 is an antidote to cell death.
In conclusion, the present data showed that: (1) both apoptosis and proliferation are elevated in the more aggressive stage of thyroid carcinoma, as is the ratio between these two parameters; (2) bcl-2 is inversely correlated with apoptosis in PTC; (3) p53 is directly cofrelated to apoptosis; and (4) none of these parameters are correlated to the outcome in patients.
